



GA N° 668353

H2020 Research and Innovation

Deliverable N°: D4.1

**Title: Dedicated webpage with secured login access
for investigators and study staff**

WP N° and Title: **WP4 - Clinical implementation and evaluation of
pre-emptive PGx**

Lead beneficiary: **P1-LUMC**

Type: **Other**

Dissemination level: **Public**

Start date of project: 01/01/2016

Duration: 60 months

Due date of deliverable: Month 18

Actual submission date: 07/09/2016 (Month 9)


Comment: [e.g. explanation for delay]

Introduction www.upgx.eu

The U-PGx website was launched in 2015 and updated after the start of U-PGx on January 1, 2016. It now contains the following public webpages, Homepage, News, Education, U-PGx, and Contact, that are described in more detail below. In the near future, a public webpage will be added regarding the U-PGx Personalized Medicine Days. This webpage will include all information about the program, venue, registration, etc. In addition, two login webpages are included, one for pharmacists and physicians (For Clinicians) and one for U-PGx consortium members (For Members).

Homepage (public)

The homepage of the dedicated webpage includes the logo and the title of the U-PGx project. It states our aim and focus and a short description of the project in lay language with appealing pictograms. The homepage also includes pictures of U-PGx consortium members, and the Scientific Advisory Board is introduced.



The screenshot shows the homepage of the U-PGx website. At the top, there is a navigation menu with links for Home, News, Education, U-PGx, For clinicians, Login Members, and Contact. The main header features a large image of a doctor and a child, with the text: "WE WANT TO MAKE EFFECTIVE TREATMENT OPTIMIZATION ACCESSIBLE TO EVERY EUROPEAN CITIZEN" and a "TELL ME MORE" button.

OUR FOCUS

We want to improve the safety and efficacy of pharmacotherapy for every European patient by enabling clinical pharmacogenomics

- SHARED EUROPEAN GUIDELINES**: Maintenance and dissemination of pharmacogenomics guidelines in the European Union
- IMPLEMENTATION AND EVALUATION**: Clinical implementation and outcome evaluation of pre-emptive pharmacogenomics in a multitude of European countries
- ENABLING TECHNOLOGIES**: Development of powerful and barrier-free clinical decision support systems and novel pharmacogenomics methodologies
- COMMUNICATION AND EDUCATION**: Development of a program to reach out to patients, health care professionals, regulatory agencies, politics and health insurance organisations

THE PROJECT

Pharmacogenomics (PGx) is the study of genetic variability affecting an individual's response to a drug. Clinical application of pharmacogenomics knowledge will result in less 'trial and error' prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in PGx and several commercially available PGx tests, its application in routine patient care remains very limited.

Immediate knowledge of relevant PGx variation, with interpretation and recommendations, without any disruption of routine clinical care is a clear advantage of the U-PGx approach.

The U-PGx consortium will address major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients' electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).

- POTENTIAL OPTIMIZATION**: 50% of elderly patients will receive drug treatment that could be optimized via PGx within the next four years.
- PHYSICIAN INTEREST**: 98% of physicians think that PGx could help to better predict drug response.
- LACK OF KNOWLEDGE**: Only 10% of physicians feel they currently have adequate knowledge and tools for PGx.


































U-PGx | Ubiquitous Pharmacogenomics







Home News Education U-PGx For clinicians Login Members Contact

OUR TEAM

A strong and efficient team of expert researchers, clinicians, companies and stakeholders



 HENK-JAN GUCHELAAR Scientific coordinator U Medical Centre Utrecht, NL	 JESSE SWEN U Medical Centre Leiden, NL	 SIR MUNIR PIRMOHAMED U of Liverpool, UK	 JULIA STINGL Federal Institute for Drug and Medical Devices, GER
 MAGNUS INGELMAN-SUNDBERG Karolinska Institute, SWE	 CHRISTINA MITROPOULOU GEMOGENA, EDUCATION, UK	 KA-CHUN CHEUNG KCOF/HKUST, HK, CN	 MATTHIAS SAUERFELD Medical University of Vienna, AUT
 ANNE CAMBRON-THOMSEN U of Toulouse, FR	 MATS KARLSSON Uppsala University, SWE	 GIUSEPPE TOFFOLI National Cancer Institute, ITA	 CRISTINA LUCIA DÁVILA-FAJARDO S. C. Gonzalez Hospital Gonzalez, ESP
 GEORGE R. PATRINO University of Patras, GRE	 VITA DOLŽAN University of Ljubljana, SLO	 MATTHIAS SCHWAB U of Stuttgart, GER	 MAREJOLEN KRIEK U Medical Centre Leiden, NL
 WENDY VAN HEEMLEN Program manager U Medical Centre Leiden, NL	 CATHELIJNE VAN DER WEIJDEN U Medical Centre Leiden, NL	 RICHARD TURNER U of Liverpool, UK	 MANDY VAN RIENEN KCOF/HKUST, HK, CN
 GERE SANDER-PLOSSMANN Medical University of Vienna, AUT	 KATHRIN BLAGOEV Medical University of Vienna, AUT	 SEBASTIAN HOFER Medical University of Vienna, AUT	 SIV JONSSON Uppsala University, SWE
 ERIKA CECCHI National Cancer Institute, ITA	 CARLOS GONZALEZ Spain	 THEODORA KATSILA University of Patras, GRE	 BARBARA JENKO Slovenia
 FRANS VAN DER VAART Royal Dutch Pharmacists Association, NL	 DANIELA STEINBERGER BioAgeCenter for Women GenetCC, GER	 VERA DENEER St. Antonius Hospital Nieuwegein, NL	

ADVISORY BOARD

 MARK J. RATAIN U of Chicago, USA	 RUSS ALTMAN Stanford University, Stanford, CA, USA	 DAN RODEN Vanderbilt University School of Medicine, Nashville, TN, USA	 MARY KELLING St. Jude Children's Research Hospital, Memphis, TN, USA
 MICHEL ECKELBALM Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, DE	 DAVID M. HAERBY Patient and Consumer Working Party of the European Medicines Agency (EMA), Bonn, Netherlands		


News (public)

The website includes a publically accessible News site where blogs about (U-)PGx news, publications and events are posted by U-PGx consortium members. If you click on the title of the News item, a page is opened where you can read the entire article.




Education (public)


The Education site contains 3 webpages: 1) Events, a calendar containing world-wide (U-) PGx conferences, courses, summer schools etc.; 2) Documents, Videos and other educational material targeted at the general public are posted here; 3) Links, hyperlinks to related websites are listed on this page.



The screenshot shows the 'Events' page on the U-PGx website. It features a navigation menu with 'Home', 'News', 'Education', 'U-PGx', 'For clinicians', 'Login/Members', and 'Contact'. Below the menu is a search bar and a 'FIND EVENTS' button. The main content is a calendar for September 2016. The calendar shows several events, including '2016 Golden Helix Summer School' on the 24th, 25th, and 26th, and '1st Annual U-PGx Consortium Meeting' on the 27th and 28th. A 'RECENT POSTS' sidebar on the right lists recent news items.




The screenshot shows the 'Documents' page on the U-PGx website. It features a navigation menu with 'Home', 'News', 'Education', 'U-PGx', 'For clinicians', 'Login/Members', and 'Contact'. Below the menu is a search bar. The main content is a document titled 'How Genetic testing can be used to personalized drug prescriptions and dosages', posted on June 23, 2016, by Marielis Vlasopoulos. The document includes a video player and a description of the video's content. A 'RECENT POSTS' sidebar on the right lists recent news items.



The screenshot shows the 'Links' page on the U-PGx website. It features a navigation menu with 'Home', 'News', 'Education', 'U-PGx', 'For clinicians', 'Login/Members', and 'Contact'. Below the menu is a search bar. The main content is a list of links to related websites, including 'The Pharmacogenomics Knowledge Base (PharmGKB)', 'European Medicines Agency, CHMP Pharmacogenomics Working Party', 'Clinical Pharmacogenomics Implementation Consortium', and 'Pharmacogenomics Research Network'. A 'RECENT POSTS' sidebar on the right lists recent news items.

U-PGx (public)

This webpage shows an overview of all the participants in the U-PGx consortium. It includes their logos and hyperlinks to the organization websites. It also indicates the U-PGx project outline of components and work packages.



Participant organisation name	Country
1. Leiden University Medical Center – LUMC (coordinator) Dept. Clinical Pharmacy & Toxicology and Dept. of Clinical Genetics H.J. Guchelaar, J.J. Swen, M. Krisk	Netherlands
2. University of Liverpool – UoL and Royal Liverpool University Hospital (RLBUTH) Dept. of Molecular & Clinical Pharmacology M. Pirmohamed, R. Turner	UK
3. The Federal Institute for Drugs and Medical Devices, Bonn – BfArM J. Stingl	Germany
4. Karolinska Institute, Stockholm – KI Dept. of Physiology & Pharmacology M. Ingelman-Sundberg	Sweden
5. The Golden Helix Foundation, London – GHXF C. Mitropoulos	UK
6. Royal Dutch Pharmacists Association, The Hague – KNMP K.C. Cheung, M. van Rhenen	Netherlands
7. Miclogis Genetic Information Management GmbH – bGM and bioLogis Center for Human Genetics, Frankfurt – bZBH D. Stohrberger	Germany
8. St. Antonius Hospital, Nieuwegein – SAZN Dept. Clinical Pharmacy V.H.M. Deneer	Netherlands
9. Medical University of Vienna – MUV Center for Med. Statistics, Informatics, and Intelligent Systems and Div. of Nephrology & Dialysis M. Sarinwald, G. Sunder-Plasmann	Austria
10. University Toulouse III Paul Sabatier – UPS A. Cambon-Thomsen	France
11. Uppsala University – UJ Dept. Pharmaceutical Biosciences M. Karlsson, S. Jönsson	Sweden
12. Centro di Riferimento Oncologico di Aviano, National Cancer Centre – CROA Experimental and Clinical Pharmacology Unit G. Toffoli, E. Cecchi	Italy
13. Servicio Andaluz de Salud, San Cecilio University Hospital Granada – SAS Dept. of Pharmacy C.L. David Fajardo	Spain
14. University of Patras – UPAT Dept. of Pharmacy G.P. Patrino	Greece
15. University of Ljubljana – UL Faculty of Medicine, Pharmacogenetics Lab. V. Dolzan	Slovenia
16. Robert Bosch Gesellschaft für Medizinische Forschung mbH, Stuttgart – RBMF Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology M. Schwab, E. Schaeffeler	Germany

U-PGx | Ubiquitous Pharmacogenomics

Home News Education U-PGx For clinicians Members Contact

Work packages

Search ...

Outline of components and Work Packages

Component I: Enabling pre-emptive testing			
WP1: Research and European PG Guidelines Leader: Royal Dutch Pharmacists Association	WP2: Training and Education Leader: WUfG	Component II: ELIS, dissemination and communication Leader: WUfG	Component III: Clinical implementation and evaluation Leader: WUfG
WP3: Genotyping technology Leader: WUfG	WP4: Clinical implementation and evaluation Leader: WUfG		
Component II: Implementation of pre-emptive PGx testing			
WP5: Health Technology Assessment (HTA) and cost-effectiveness analysis Leader: WUfG	WP6: Training and education of health care professionals, patients and other stakeholders Leader: WUfG	WP7: IT solutions and clinical decision support systems for incorporation in clinical workflows Leader: WUfG	WP8: Ethics, Legal and Societal Implications (ELSI) Leader: WUfG
WP9: Clinical implementation and evaluation of pre-emptive PGx Leader: WUfG	WP10: A next step into the future: Systems pharmacology and gene-drug-drug interactions Leader: WUfG	WP11: A next step into the future: Next generation sequencing (NGS) Leader: WUfG	WP12: Dissemination and communication, including regulatory, insurance companies Leader: WUfG
Component III: A next step in the future			
WP13: Systems Pharmacology and Gene-Drug-Drug Interactions Leader: WUfG	WP14: Next Generation Sequencing (NGS) Leader: WUfG		

WP1: Project management and coordination
WP2: Towards shared European Guidelines for PGx
WP3: Genotyping technology
WP4: Clinical implementation and evaluation of pre-emptive PGx
WP5: Health Technology Assessment (HTA) and cost-effectiveness analysis
WP6: Training and education of health care professionals, patients and other stakeholders
WP7: IT solutions and clinical decision support systems for incorporation in clinical workflows
WP8: Ethics, Legal and Societal Implications (ELSI)
WP9: A next step into the future: Systems pharmacology and gene-drug-drug interactions
WP10: A next step into the future: Next generation sequencing (NGS)
WP11: Dissemination and communication, including regulatory, insurance companies

Contact (public)

The Contact webpage contains the names and email addresses of the U-PGx project manager, coordinator, component leaders and webmaster.

U-PGx | Ubiquitous Pharmacogenomics

Home News Education U-PGx For clinicians Members Contact

Search ...

Contact

Project Manager:
 Wendy van Hemmen
 E-mail: wvanhemmen[at]lumc.nl

Scientific coordinator:
 Prof. Dr. Henk-Jan Guchelaar
 E-mail: H.J.Guchelaar[at]lumc.nl

Component Leaders:
 Component I: Matthias Samwald
 E-mail: matthias.samwald[at]medunivwien.ac.at
 Component II: Jesse Swen
 E-mail: jswen[at]lumc.nl
 Component III: Matthias Schwab
 E-mail: matthias.schwab[at]ipk-stuttgart.de
 Component IV: Christina Mitropoulou
 E-mail: cmitropoulou[at]goldenhelix.org


Questions about the website:
 Manolis Vrienas
 E-mail: vrienas[at]gmail.com

RECENT POSTS

- A brighter future for the implementation of pharmacogenomic testing.
- David Haery joins U-PGx advisory board
- 17th Golden Helix Pharmacogenomics Day in Rotterdam
- U-PGx collaborates with Teri Kleis, co-principal investigator of PharmGKB and CPIC
- Mary Relling joins U-PGx advisory board

For Clinicians (login)

This webpage contains an anonymous questionnaire to evaluate the views and knowledge of current drug prescribers on pharmacogenomics and its role in individualizing patient treatment (see Deliverable report D6.3). The questionnaire is available in English, Spanish and Greek.



For members (login)

The member-area on the website contains a page where news items are posted that are meant for consortium members only. In addition, this area contains a repository where all documents are posted and shared among the consortium:

- Agreements: GA, CA, amendments, CDAs, MTAs, etc.;
- Component I: Minutes and documents regarding WP2, 3, 6 and 7;
- Component II: Minutes and documents regarding WP4 and 5;
- Component III: Minutes and documents regarding WP9 and 10;
- Component IV: Minutes and documents regarding WP8 and 11;
- Consortium meetings: Programs and reports of Kick-off, MTR, Annual meetings, etc.;
- Dissemination and Outreach: Abstracts, peer-reviewed publications, popular articles etc.;
- Management: Minutes Executive Board meetings and General Assembly, information regarding personnel and finances, etc.;
- Reporting: Deliverable reports, Internal progress reports, periodic reports, etc.



U-PGx | Ubiquitous Pharmacogenomics

Home News Education U-PGx For clinicians Members Contact

members

Study randomisation
Posted on August 10, 2016 by Wendy van Hemmen

In the first week of August, the randomisation for the U-PGx implementation study took place. The randomisation results have been incorporated in the study protocol which is now almost completed.

Posted in [members](#) [Edit](#)

1st Annual U-PGx Consortium Meeting
Posted on May 19, 2016 by Wendy van Hemmen

The first annual U-PGx consortium meeting will take place in Athens on September 27-28, 2016. Meeting venue: The Divani Palace Acropolis hotel, Athens, Greece.

Posted in [members](#) [Edit](#)

Agenda for February U-PGx meeting in Rotterdam
Posted on February 5, 2017 by marthoos_jansveld

The harmonized schedule of the U-PGx meeting at the Erasmus Medical Center in Rotterdam has been released. Meeting venue: Dept. Clin. Chemistry, Erasmus MC, Room Na-402 Wytenavweg 80, Rotterdam (NL). Attendees Day 1 Day 2

Posted in [members](#) [Edit](#)

RECENT POSTS

- A brighter future for the implementation of pharmacogenomic testing.
- David Haeryn joins U-PGx advisory board
- 17th Golden Helix Pharmacogenomics Day in Rotterdam
- U-PGx collaborates with Teri Klein, co-principal investigator of PharmGKB and CPIC
- Mary Relling joins U-PGx advisory board

U-PGx | Ubiquitous Pharmacogenomics

Home News Education U-PGx For clinicians Members Contact

Repository

Home > Component II

WP4
WP5

Document	Date	View Details
Minutes WP4 2016-09-05	September 6, 2016	View Details
WP4 Study protocol draft 3	August 10, 2016	View Details
Minutes WP4 2016-08-08	August 10, 2016	View Details
Minutes WP4 2016-07-26	August 4, 2016	View Details
Minutes WP4 2016-07-12	August 4, 2016	View Details
Presentation Data Collection WP4 2016-06-07	June 16, 2016	View Details
Minutes WP4 2016-06-07	June 16, 2016	View Details
Minutes WP4 2016-04-20	June 14, 2016	View Details

RECENT POSTS

- A brighter future for the implementation of pharmacogenomic testing.
- David Haeryn joins U-PGx advisory board
- 17th Golden Helix Pharmacogenomics Day in Rotterdam
- U-PGx collaborates with Teri Klein, co-principal investigator of PharmGKB and CPIC
- Mary Relling joins U-PGx advisory board

U-PGx | Ubiquitous Pharmacogenomics

Home News Education U-PGx For clinicians Members Contact

Repository

Home > Management

EB meetings
Personnel and Finance

Document	Date	View Details
Minutes EB meeting 2016-08-03	August 10, 2016	View Details
Declaration Person working exclusively on H2020 action	August 4, 2016	View Details
Template EU timesheet H2020	August 4, 2016	View Details
Presentation Employment of Personnel 2016-05-19	August 4, 2016	View Details
Budget Transfer Model	August 4, 2016	View Details
Procedure Budget Transfer	August 4, 2016	View Details
Minutes EB meeting 2016-05-31	June 28, 2016	View Details
Minutes EB meeting 2016-03-31	June 14, 2016	View Details

RECENT POSTS

- A brighter future for the implementation of pharmacogenomic testing.
- David Haeryn joins U-PGx advisory board
- 17th Golden Helix Pharmacogenomics Day in Rotterdam
- U-PGx collaborates with Teri Klein, co-principal investigator of PharmGKB and CPIC
- Mary Relling joins U-PGx advisory board